Previous pre-clinical work investigated the ability of the second-generation AR antagonist enzalutamide to induce radiosensitivity in LNCaP and C4-2 PCa cells grown media with or without testosterone supplementation. This evidence concerns the gene AR and posterior cortical atrophy.